Genetics in Parkinson's Disease: Behavioral and Cognitive Outcomes
NCT06329739
Summary
The genetic landscape of Parkinson's disease (PD) is characterised by rare high penetrance pathogenic variants causing familial disease, genetic risk factor variants driving PD risk in a significant minority in PD cases and high frequency, low penetrance variants, which contribute a small increase of the risk of developing sporadic PD. This knowledge has the potential to have a major impact in the clinical care of people with PD. The goal of this observational study is to evaluate the impact of genetic mutation on behavior and cognition in PD patients. Patients will be assessed over time using test, questionnaire and standardised clinica scales. An initial assessment and annual follow-up assessments will be carried out for 5 years. Researchers will compare data collected from patients with genetic mutation versus patients without mutation.
Eligibility
Inclusion Criteria: * diagnosed with Parkinson's Disease (PD) * in use of dopaminergic medication (L-Dopa and/or dopamine agonists) * genetic testing for mendelian forms of PD * able to provide informed consent to participate in the study Exclusion Criteria: * Patients underwent Deep Brain Stimulation (DBS) treatment
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06329739